|
T8684 |
Sotorasib
|
AMG-510 |
Ras
|
|
Sotorasib (AMG-510) is an orally active and selective covalent inhibitor of KRAS G12C. Sotorasib binds to the GDP state of the inactive conformation of KRAS G12C and inhibits KRAS and its downstream signaling. Sotorasib ... |
|
T7194 |
CM-272
|
|
Apoptosis
,
DNA Methyltransferase
,
Histone Methyltransferase
|
|
CM-272 is a dual G9a/DNA methyltransferases (DNMTs) inhibitor. |
|
T16813 |
RX-3117
|
fluorocyclopentenylcytosine,TV-1360 |
Nucleoside Antimetabolite/Analog
|
|
RX-3117 (fluorocyclopentenylcytosine) is a novel a cytidine analog. RX-3117 displays anticancer activity in several cancer cell lines, including gemcitabine-resistant variants. |
|
T8842 |
IMT1B
|
3-Piperidinecarboxylic acid, 1-[(2R)-2-[[4-(2-chloro-4-fluorophenyl)-2-oxo-2H-1-benzopyran-7-yl]oxy]-1-oxopropyl]-, (3S)-,LDC203974 |
Others
,
DNA/RNA Synthesis
|
|
IMT1B (LDC203974) is an orally administered, specific noncompetitive allosteric inhibitor of the mitochondrial RNA polymerase (POLRMT), effectively suppressing mitochondrial DNA (mtDNA) expression. This action confers it... |
|
T26866 |
BMS-960
|
BMS 960,BMS960 |
S1P Receptor
|
|
BMS-960 is an S1P agonist with potential anti-tumour activity for cancer research. |
|
T67699L |
ALK/ROS1 inhibitor 2e HCL
|
(R)-1-(2-((2-methoxy-4-(piperazin-1-yl)phenyl)amino)pyridin-4-yl)-N-(4-(trifluoromethoxy)benzyl)piperidine-3-carboxamide hydrochloride(2365497-12-5 Free base) |
Apoptosis
|
|
ALK/ROS1 inhibitor 2e HCL possesses anti-apoptotic, anti-proliferative and anti-tumour activities. |
|
T28911 |
Tafetinib
|
SIM-010603,SIM010603,SIM 010603 |
Tyrosine Kinases
|
|
Tafetinib (SIM-010603) is a novel potent and orally available tyrosine kinase inhibitor with anti-angiogenic and anti-tumour activity. |
|
T25384 |
Erbulozole
|
R-55104,R55104,R 55104 |
Microtubule Associated
|
|
Erbulozole (R 55104) is a potent synthetic microtubule inhibitor with anti-invasive, anti-tumour and radiosensitising activity that induces Wernicke's encephalopathy-like neurotoxicity. |
|
T68152 |
Talmetacin
|
|
Others
|
|
Talmetacin has anti-inflammatory and analgesic and anti-tumour activity and can be used to study cardiovascular disease. |
|
T14893 |
CC-885
|
|
Others
,
Ligand for E3 Ligase
|
|
CC-885 is a modulator of cereblon (CRBN). It has potent anti-tumour activity. |
|
T25969 |
Poloxin-2
|
Poloxin2,Poloxin 2 |
PLK
|
|
Poloxin-2 is a potent and selective Plk1 PBD inhibitor with anti-tumour activity that reduces the protein level of Plk1 in HeLa cells. |
|
T83646 |
(S)-OSMI 3
|
Ent-OSMI-3 |
Others
|
|
(S)-OSMI 3 (Ent-OSMI-3) has anti-inflammatory and anti-tumour activity and can be used to study diabetes and neurodegenerative diseases. |
|
T77728 |
Tubulin polymerization-IN-55
|
|
Microtubule Associated
|
|
Tubulin polymerization-IN-55 is a potent Tubulin Polymerization inhibitor with potential anti-angiogenic and anti-tumour activity, showing anti-proliferative effects against A549, K562, HepG2, MDA-MB-231 and HFL-1. |
|
T7670 |
Mavacoxib
|
|
COX
|
|
Mavacoxib is a selective inhibitor of cyclooxygenase-2 (COX-2) ,with Anti-Tumour activity. |
|
T77407 |
Ensituximab
|
NPC-1C,NEO-102,NEO-101 |
|
|
Ensituximab (NEO-102) is a quasi-selective IgG1 monoclonal antibody against the MUC5AC variant with anti-tumour activity that inhibits colorectal and pancreatic cancer. |
|
T64167 |
Ifebemtinib
|
IN-10018,BI-853520 |
FAK
|
|
Ifebemtinib (BI-853520) is an orally active and potent inhibitor of adhesion plaque kinase (FAK) (IC50=1 nM) with anti-tumour activity that inhibits globule formation and in situ tumour growth in malignant pleural mesoth... |
|
T61486 |
DHFR-IN-4
|
|
DHFR
|
|
DHFR-IN-4 is a potent dihydrofolate reductase (DHFR) inhibitor with anti-tumour activity, inhibits EGFR and HER2 and can be used to study pancreatic cancer. |
|
T36848 |
Combretastatin A-1
|
Combretastatin A1 |
Akt
,
Microtubule Associated
|
|
Combretastatin A-1 is a potent microtubule inhibitor with anti-tumour and anti-vascular activity, acting through microtubule protein depolymerisation-mediated inactivation of AKT to inhibit the Wnt/β-catenin pathway, and... |
|
T77733 |
TNKS-2-IN-2
|
|
Wnt/beta-catenin
|
|
TNKS-2-IN-2 is a novel and potent TNKS2 selective inhibitor (IC50: 22 nM) with potential anti-tumour activity for the study of colon cancer lung cancer and breast cancer. |
|
T15771 |
Lobaplatin
|
D-19466 |
DNA Alkylation
|
|
Lobaplatin (D-19466) (D-19466) is a diastereometric mixture of platinum(II) complexe. Lobaplatin (D-19466) is a third-generation platinum anti-neoplastic agent which shows activity for a variety of tumour types and is a ... |
|
T72029 |
CDK8-IN-13
|
|
Apoptosis
,
CDK
|
|
CDK8-IN-13 is a CDK8 inhibitor (IC50: 51.9 nM) with potent, selective and oral activity. CDK8-IN-13 induces apoptosis and reduces the expression of p-STAT1 S727 and p-STAT5 S726. CDK8-IN-13 exhibits anti-tumour activity... |
|
T33701 |
NM-3
|
NM-3,isocoumarin,NM 3,Isocoumarin NM-3,NM3 |
Apoptosis
,
Reactive Oxygen Species
|
|
NM-3 is an orally available anti-angiogenic inhibitor with anti-tumour activity.NM-3 is used as a radiation modulator in vitro and in vivo.NM-3 inhibits vascular endothelial growth factor (VEGF), thereby inhibiting the p... |
|
T15615 |
JND3229
|
|
EGFR
|
|
JND3229 is a reversible EGFRC797S inhibitor with IC50 values of 5.8, 6.8 and 30.5 nM for EGFRL858R/T790M/C797S, EGFRWT and EGFRL858R/T790M, respectively. JND3229 has good anti-proliferative activity and can effectively i... |
|
T64066 |
CSF1R-IN-3
|
|
c-Fms
,
CSF-1R
|
|
CSF1R-IN-3 is an orally effective CSF-1R inhibitor with an IC50 value of 2.1 nM. CSF1R-IN-3 has anti-proliferative activity against colorectal cancer cells. CSF1R-IN-3 exhibits anti-tumour effects and immune enhancing ef... |
|
T27417L |
Glutathione arsenoxide hydrochloride
|
GSAO HCl,Glutathione arsenoxide hydrochloride(1271726-51-2 Free base) |
Apoptosis
,
AChR
|
|
Glutathione arsenoxide hydrochloride (Glutathione arsenoxide hydrochloride(1271726-51-2 Free base)) is a potentially active anti-cancer molecule and inhibitor of tumour metabolism. glutathione arsenoxide hydrochloride ta... |
|
T30759 |
CB 1837
|
CB1837,CB-1837,AI3-51871,NSC 3375 |
|
|
CB 1837 is an anti-tumour agent. |
|
T27873 |
LY 135114
|
LY135114,LY-135114 |
|
|
LY 135114 is a metabolite of LY 195448, which is a phenethanolamine with anti-tumour activity. |
|
T27891 |
LY195448 HCl
|
LY195448,UNII-BR0DFE3GF6,LY-195448 |
|
|
LY195448 HCl is a phenethanolamine shown anti-tumour activity. It blocks cells at metaphase. |
|
T26469 |
A-176120
|
|
|
|
A-176120 is a potent farnesyl pyrophosphate (FPP) analogues, it selectively inhibits farnesyltransferase. It has anti-angiogenic potential and may reduce H-ras NIH3T3 tumour growth. |
|
T62601 |
Anticancer agent 48
|
|
|
|
Anticancer agent 48 (compound 48) is a broad-spectrum anticancer agent with anti-proliferative activity. anticancer agent 48 inhibits microtubule protein polymerisation and has anti-tumour activity in vivo. anticancer ag... |
|
T64128 |
Antitumor agent-56
|
|
|
|
Antitumor agent-56 is an orally active triptolide derivative that significantly inhibits melanoma growth, exhibiting anti-tumour, anti-inflammatory and NO-releasing effects. |
|
T62875 |
NF-κB-IN-3
|
|
|
|
NF-κB-IN-3 (Compound 2) is an NF-κB inhibitor (IC50: 0.70 μM) and can be used as an anti-tumour agent. |
|
T62602 |
Anticancer agent 49
|
|
|
|
Anticancer agent 49 (compound 69) is a broad-spectrum anticancer agent with anti-proliferative activity. anticancer agent 48 inhibits microtubule protein aggregation and has in vivo antitumour activity. anticancer agent ... |
|
T64025 |
Top/HDAC-IN-2
|
|
|
|
Top/HDAC-IN-2 (45b) is a dual inhibitor of Top and HDAC that induces apoptosis and exhibits significant anti-tumour effects. |
|
T62828 |
FRα-IN-1
|
|
|
|
FRα-IN-1 (Compound 4) is a tumour targeting agent. FRα-IN-1 exhibits selective anti-cancer effects on FRα and FRβ expressing cells. |
|
T62970 |
CDK1-IN-1
|
|
|
|
CDK1-IN-7 is a potent inhibitor of CDK1 with an IC50 value of 161.2 nM for CDK1/CycB. CDK1-IN-7 induces apoptosis in a p53-dependent manner via the apoptosis-intrinsic pathway. CDK1-IN-7 selectively acts on tumour tissue... |
|
T72976 |
TGFβRI-IN-6
|
|
|
|
TGFβRI-IN-6 is a potent TGFβRI inhibitor with an IC50 value of 0.55 nM.TGFβRI-IN-6 has the potential to enhance anti-tumour immunity. |
|
T63922 |
ERα degrader 5
|
|
|
|
ERα degrader 5 is an orally active, selective estrogen receptor (ER) reducer that acts on ERα (EC50: 1.1 nM). ERα degrader 5 shows anti-tumour effects in vivo. |
|
T73186 |
HPK1-IN-31
|
|
|
|
HPK1-IN-31 inhibitor with an IC 50 value of 0.8 nM. HPK1-IN-31 has anti-tumour activity and has great potential for immunotherapy . |
|
T64259 |
GLS1 Inhibitor-5
|
|
|
|
GLS1 Inhibitor-5 (compound 24y) is a selective, orally active inhibitor of glutaminase 1 (GLS1) (IC50: 68 nM). gLS1 Inhibitor-5 induces apoptosis and exhibits anti-tumour effects. |
|
T63103 |
PRMT5-IN-17
|
|
|
|
PRMT5-IN-17 (Compound 6) is a PRMT5 inhibitor that exhibits antitumour activity. PRMT5, a protein arginine methyltransferase, is a novel anti-tumour target associated with epigenetic modifications. |
|
T35916 |
Simotinib
|
AL-6802,SIM-6802 |
EGFR
|
|
Simotinib (AL-6802) is a selective and orally bioactive EGFR tyrosine kinase inhibitor (IC50: 19.9 nM) with anti-tumour activity for the study of non-small cell lung cancer. |
|
T63861 |
CCT373566
|
|
|
|
CCT373566 is a potent, orally active degrader of the transcriptional repressor BCL6 (IC50: 2.2 nM). CCT373566 exhibits significant anti-proliferative effects in vitro and reduces tumour growth in vivo. |
|
T63934 |
PAK4-IN-1
|
|
|
|
PAK4-IN-1 is a selective, potent, orally active PAK4 inhibitor that is stable under both acidic and neutral conditions.PAK4-IN-1 exhibits good anti-tumour effects in vivo. |
|
T64093 |
KRAS G12C inhibitor 44
|
|
|
|
KRAS G12C inhibitor 44 is a potent, orally active KRAS G12C inhibitor. KRAS G12C inhibitor 44 exhibits anti-proliferative effects in MIA PaCA-2 (IC50: 0.016 μM), H358 cells (IC50: 0.028 μM). inhibitor 44 has anti-tumour ... |
|
T63159 |
Anticancer agent 28
|
|
|
|
Anticancer agent 28 showed good anti-tumour effects in vivo in H22 allograft mice. anticancer agent 28 was 50 times more potent than Oridonin against K562 cells with an IC50 value of 0.09 μM. |
|
T60590 |
Chloropyramine
|
|
|
|
Chloropyramine is a competitive reversible H1 receptor antagonist that can be used in allergic conditions research, for example, conjunctivitis and bronchial asthma. Chloropyramine also shows anti-tumour activity in brea... |
|
T62746 |
EGFR/HER2/CDK9-IN-1
|
|
|
|
EGFR/HER2/CDK9-IN-1 (Compound 4) is a potent EGFR/HER2/CDK9 inhibitor with IC50 values of 90.17, 131.39 and 67.04 nM. EGFR/HER2/CDK9-IN-1 exhibits significant anti-tumour effects. |
|
T63138 |
PRMT5-IN-16
|
|
|
|
PRMT5-IN-16 (Compound 20) is a PRMT5 inhibitor with antitumour effects. PRMT5, a protein arginine methyltransferase, is a novel anti-tumour target associated with epigenetic modifications. |
|
T62763 |
VEGFR-2-IN-12
|
|
|
|
VEGFR-2-IN-12 (compound 6g), a 2-oxoquinoxalinyl-1,2,4-triazole, is a potent inhibitor of VEGFR-2 (IC50: 0.037 μM). VEGFR-2-IN-12 has anti-tumour effects. |
